Akoya Biosciences, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Akoya Biosciences, Inc. (NYSE: AKYA) develops and commercializes spatial biology platforms that enable researchers to perform tissue analysis at the single-molecule level, providing comprehensive insights into cellular organization, protein function, and disease mechanisms. The company's core products include the PhenoCycler instrument and PhenoImager HT platform for high-throughput, whole-slide spatial phenotyping; PhenoCycler-Fusion for targeted protein analysis; and the CosMx Spatial Molecular Imager (SMI) for single-cell and subcellular transcriptomics and proteomics with over 6,000 RNA and 1,000 protein targets; as well as corresponding reagents, consumables, and cloud-based analytics software such as the Discover platform. These offerings support applications in oncology, immunology, neuroscience, and infectious diseases, serving academic institutions, biopharmaceutical companies, and contract research organizations primarily in North America, Europe, and Asia-Pacific. Founded in 2015 and headquartered in Marlborough, Massachusetts, Akoya operates as a leader in the spatial biology segment of the life sciences tools industry, with no major subsidiaries or parent entities. In the past 1-2 years, Akoya has pursued strategic expansions including a multi-year collaboration with Tempus AI announced in March 2025 to advance precision oncology through spatial biology integration; a deepened partnership with Roche in 2024 to co-develop companion diagnostics using the PhenoImager platform; the launch of CosMx SMI v2 in late 2024 with enhanced automation and throughput capabilities; and a $40 million debt financing round in Q1 2025 to support commercial scaling and R&D amid ongoing revenue growth in spatial omics consumables.
AKOYA BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal
Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates
Akoya Biosciences Reports First Quarter 2025 Financial Results
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Quanterix and Akoya Biosciences Announce Amended Merger Agreement
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore
Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences
Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences
Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call
Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner